DL-Buthionine- (S, R) -sulfoximine (hydrochloride)
DL-Buthionine- (S, R) -sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
Product Specifications
Product Name Alternative
Buthionine sulfoximine (hydrochloride) ; BSO (hydrochloride)
UNSPSC
12352211
Target
Ferroptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/d-l-buthionine-s-r-sulfoximine-hydrochloride.html
Purity
99.09
Solubility
DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 100 mg/mL (ultrasonic)
Smiles
OC(C(N)CCS(CCCC)(=N)=O)=O.[H]Cl
Molecular Formula
C8H19ClN2O3S
Molecular Weight
258.77
References & Citations
[1]Griffith OW, et al. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine) . J Biol Chem. 1979 Aug 25;254 (16) :7558-60.|[2]Vanhoefer U, et al. d, l-buthionine- (S, R) -sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996 Dec;2 (12) :1961-8.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Redox Biol. 2025 Apr:81:103567.|ACS Appl Mater Interfaces. 2025 Apr 2;17 (13) :19367-19381.|Acta Pharmacol Sin. 2025 Jun 23.|Adv Sci (Weinh) . 2023 Aug;10 (22) :e2206798.|Algal Res. 2025 Mar.|Antimicrob Agents Chemother. 2025 Aug 18:e0047125.|Biochem Biophys Res Commun. 2024 Jul 23:733:150436.|Biochem Genet. 2024 Sep 24.|bioRxiv. 2025 March 15.|Cancer Res. 2025 Aug 21.|Cell Death Dis. 2025 Mar 20;16 (1) :193.|Cell Signal. 2025 Jan 3:111583.|Ecotoxicol Environ Saf. 2022 Dec 1:247:114263.|Eur J Med Chem. 2024 Jan 15:264:115997.|FASEB J. 2024 Jul 31;38 (14) :e23844.|Free Radic Biol Med. 2024 Jun 19:S0891-5849 (24) 00531-8.|Gene. 2025 Oct 20:970:149785.|Int Immunopharmacol. 2025 May 11:158:114813.|J Control Release. 2025 Sep 30;388 (Pt 1) :114283.|J Invest Dermatol. 2025 Jul;145 (7) :1693-1705.e2.|Med Oncol. 2023 Apr 10;40 (5) :141.|Mol Carcinog. 2025 Sep 25.|Mol Cell Biochem. 2021 Mar;476 (3) :1631-1642.|Nat Commun. 2024 Aug 30;15 (1) :7522.|Nucleic Acids Res. 2020 Sep 18;48 (16) :9109-9123.|Res Sq. 2024 Sep 12:rs.3.rs-5065904.|Research Square Preprint. 2023 May 24.|Research Square Print. 2023 Mar 24.|Sci Adv. 2025 Aug 22;11 (34) :eadw6926.|Small. 2021 Dec;17 (50) :e2103984.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1110960-01 0.02 mg (E-Coli)
Recombinant African swine fever virus Protein MGF 360-2L (War-173)
Ask
View Details MBS1110960-02 0.02 mg (Yeast)
Recombinant African swine fever virus Protein MGF 360-2L (War-173)
Ask
View Details MBS1110960-03 0.1 mg (E-Coli)
Recombinant African swine fever virus Protein MGF 360-2L (War-173)
Ask
View Details 
MBS1110960-04 0.1 mg (Yeast)
Recombinant African swine fever virus Protein MGF 360-2L (War-173)
Ask
View Details